The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken

Jens Hillengass,J. Stoll,C. M. Zechmann,Christina Kunz,Barbara Wagner,Christiane Heiss,M. Sumkauskaite,Thomas Moehler,Heinz-Peter Schlemmer,H. Goldschmidt,Stefan Delorme

The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken

2015

Jens Hillengass
J. Stoll
C. M. Zechmann
Christina Kunz
Barbara Wagner
Christiane Heiss
M. Sumkauskaite
Thomas Moehler
Heinz-Peter Schlemmer
H. Goldschmidt
Stefan Delorme

Objectives The current analysis investigated the prognostic significance of gadopentetate dimeglumine on survival and renal function in patients with monoclonal plasma cell disorders.

Keywords:

Renal function
Radiology
Gadolinium
Pathology
Monoclonal
Magnetic resonance imaging
Plasma cell
Paraproteinemias
Medicine
Kidney
Multiple myeloma
Prospective cohort study
Interventional radiology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations